Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.drreddys.com | |
Market Cap | 76,011.65 Cr. | |
Enterprise Value(EV) | 76,090.75 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 218.83 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 20.86 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.17 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 1,356.34 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.37 | Calculated using Price: 4,564.50 |
Dividend Yield | 0.66 | Period Ending 2022-03 |
No. of Shares Subscribed | 16.65 Cr. | 166,527,876 Shares |
FaceValue | 5 | |
Company Profile | ||
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations. |
1 Day |
|
+0.80% |
1 Week |
|
+1.98% |
1 Month |
|
+5.87% |
3 Month |
|
+7.17% |
6 Month |
|
+4.71% |
1 Year |
|
+5.62% |
2 Year |
|
+3.61% |
5 Year |
|
+119.19% |
10 Year |
|
+158.42% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 27.88 | 26.63 | 18.95 | 10.20 | 7.40 | 14.75 | 13.76 | 11.82 | 11.93 | |
Return on Capital Employed (%) | 25.00 | 22.70 | 19.55 | 9.77 | 8.21 | 13.66 | 11.12 | 15.49 | 14.59 | |
Return on Assets (%) | 13.47 | 13.67 | 11.05 | 6.14 | 4.23 | 8.86 | 9.20 | 8.21 | 8.08 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 7,865 | 9,853 | 12,570 | 12,262 | 12,572 | 14,024 | 15,599 | 17,642 | 19,212 | 20,775 | |
Non Curr. Liab. | 2,182 | 1,678 | 877 | 456 | 2,538 | 2,113 | -808 | -197 | -508 | -345 | |
Curr. Liab. | 5,790 | 6,821 | 6,347 | 8,420 | 6,894 | 5,897 | 7,214 | 8,104 | 9,766 | 7,987 | |
Minority Int. | |||||||||||
Equity & Liab. | 15,838 | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 28,417 | |
Non Curr. Assets | 5,512 | 6,476 | 8,000 | 11,454 | 11,505 | 10,924 | 9,406 | 10,998 | 10,682 | 11,163 | |
Curr. Assets | 10,326 | 11,877 | 11,794 | 9,684 | 10,498 | 11,110 | 12,599 | 14,535 | 17,788 | 17,254 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 15,838 | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 28,417 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 13,415 | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 23,829 | |
Other Income | 196 | 275 | 295 | 172 | 155 | 338 | 621 | 291 | 485 | 1,075 | |
Total Income | 13,611 | 15,298 | 15,863 | 14,368 | 14,436 | 15,786 | 18,138 | 19,339 | 22,030 | 24,905 | |
Total Expenditure | -10,165 | -11,530 | -11,983 | -11,724 | -11,930 | -12,270 | -15,047 | -15,178 | -17,778 | -18,600 | |
PBIDT | 3,446 | 3,769 | 3,880 | 2,644 | 2,506 | 3,516 | 3,091 | 4,161 | 4,252 | 6,305 | |
Interest | -153 | -109 | -83 | -63 | -79 | -89 | -98 | -97 | -96 | -139 | |
Depreciation | -648 | -760 | -939 | -1,027 | -1,077 | -1,135 | -1,163 | -1,229 | -1,165 | -1,228 | |
Taxation | -683 | -563 | -751 | -297 | -438 | -386 | 140 | -932 | -879 | -1,334 | |
Exceptional Items | |||||||||||
PAT | 1,963 | 2,336 | 2,108 | 1,257 | 912 | 1,950 | 2,026 | 1,952 | 2,183 | 3,604 | |
Minority Interest | |||||||||||
Share Associate | 23 | 35 | 34 | 40 | |||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 1,963 | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,183 | 3,644 | |
Adjusted EPS | 115 | 137 | 125 | 78 | 57 | 117 | 122 | 117 | 131 | 219 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 1,378 | 1,970 | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | |
Cash Fr. Inv. | -1,446 | -1,694 | -2,265 | -2,039 | -1,840 | -1,488 | -773 | -492 | -2,266 | -2,639 | |
Cash Fr. Finan. | -157 | -24 | -433 | -1,700 | -369 | -444 | -2,133 | -2,516 | -30 | -242 | |
Net Change | -225 | 251 | -174 | -477 | -65 | -129 | -35 | -24 | 1,275 | -70 | |
Cash & Cash Eqvt | 520 | 862 | 583 | 492 | 378 | 254 | 223 | 196 | 1,482 | 1,485 |
Thu, 23 Mar 2023
Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Thu, 23 Mar 2023
Board Meeting Intimation for Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On March 31 2023 And To Recommend Dividend If Any For The Financial Year 2022-23. DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2023 and to recommend dividend if any for the financial year 2022-23. |
Thu, 23 Mar 2023
Closure of Trading Window The trading window for dealing in securities of the Company will be closed from March 25 2023 to May 12 2023 (both days inclusive). |
Wed, 29 Mar 2023 |
|
|
|
|
|